Nivo-BeGEV as Preparation for Autologous Hematopoietic Stem Cell Transplantation in Relapsed/Refractory Classical Hodgkin Lymphoma: Results of a Multi-Center Prospective Clinical Study

Aim. To assess efficacy and safety of the Nivo-BeGEV (nivolumab combined with bendamustine, gemcitabine, and vinorelbine) immunochemotherapy in patients with relapsed/refractory (r/r) classical Hodgkin lymphoma (cHL) selected as candidates for autologous hematopoietic stem cell transplantation (auto...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Yana Konstantinovna Mangasarova, T. N. Moiseeva, O. V. Margolin, L. G. Gorenkova, E. S. Nesterova, F. E. Babaeva, M. O. Bagova, E. A. Fastova, R. R. Abdurashidova, L. S. Al-Radi, E. I. Dorokhina, E. M. Volodicheva, V. A. Lapin, O. S. Samoilova, S. K. Kravchenko, A. U. Magomedova, E. E. Zvonkov
פורמט:	Artigo
שפה:	Russo
יצא לאור:	Practical Medicine Publishing House 2023-06-01
סדרה:	Клиническая онкогематология
נושאים:	classical hodgkin lymphoma nivo-begev immunochemotherapy autologous hematopoietic stem cell transplantation immune checkpoint inhibitors relapse refractory course
גישה מקוונת:	https://bloodjournal.ru/index.php/coh/article/view/35
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!